GV Research Platform and BeCytes Partner to Enhance Access to Certified Hepatocytes & Biological Samples, Advancing Biopharma Research in India
Source: Businesswire India
Business Wire India
GV Research Platform (GVRP), a leading provider of preclinical research solutions, has announced a strategic partnership with BeCytes Biotechnologies to expand access to high-quality human and animal-derived biological materials for drug discovery and toxicology research in India.
This collaboration leverages BeCytes’ specialized expertise in tissue procurement, primary cell isolation, and in vitro models, enabling Indian researchers to utilize cutting-edge tools for more predictive and translational studies. As part of this partnership, GVRP will facilitate the availability of cryopreserved hepatocytes, hepatic and skin cells, subcellular fractions, and customized cell isolation services—critical resources for drug metabolism, safety assessment, and disease modeling.
Bridging Innovation and Accessibility
“As India’s biomedical research landscape continues to expand, access to high-quality biological models remains a key challenge,” said Kalyan Korisapati, Co-Founder & Group CEO of GVRP. “By partnering with BeCytes, we are closing this gap and ensuring that researchers in India have seamless access to best-in-class hepatic cell models, including disease models such as NASH and Liver 3D Spheroids functional models, to advance their discoveries.”
BeCytes Biotechnologies, headquartered in Barcelona, Spain, has a proven track record of supplying primary human and animal-derived cells to researchers worldwide. Their expertise in cell characterization and in vitro model development ensures consistency and reliability, addressing a critical need in preclinical drug screening and toxicology studies.
“We are excited to collaborate with GVRP to expand our global reach and empower researchers in India with reliable cell-based solutions,” said Jordi Xapellí, the CEO of BeCytes Biotechnologies “With GVRP’s established presence and commitment to research excellence, this partnership will drive impactful scientific advancements.”
Empowering Preclinical Research in India
With AAALAC International accredited and OECD-GLP compliant facilities located in Genome Valley, Hyderabad, GVRP is well-positioned to support the seamless distribution of BeCytes’ offerings. This partnership underscores both organizations’ commitment to enhancing the quality and reproducibility of preclinical research, fostering innovation, and supporting drug development efforts in India and beyond.
For media inquiries and further details, please contact:
E. [email protected] | www.gvrp.in | www.becytes.com
GV Research Platform (GVRP), a leading provider of preclinical research solutions, has announced a strategic partnership with BeCytes Biotechnologies to expand access to high-quality human and animal-derived biological materials for drug discovery and toxicology research in India.
This collaboration leverages BeCytes’ specialized expertise in tissue procurement, primary cell isolation, and in vitro models, enabling Indian researchers to utilize cutting-edge tools for more predictive and translational studies. As part of this partnership, GVRP will facilitate the availability of cryopreserved hepatocytes, hepatic and skin cells, subcellular fractions, and customized cell isolation services—critical resources for drug metabolism, safety assessment, and disease modeling.
Bridging Innovation and Accessibility
“As India’s biomedical research landscape continues to expand, access to high-quality biological models remains a key challenge,” said Kalyan Korisapati, Co-Founder & Group CEO of GVRP. “By partnering with BeCytes, we are closing this gap and ensuring that researchers in India have seamless access to best-in-class hepatic cell models, including disease models such as NASH and Liver 3D Spheroids functional models, to advance their discoveries.”
BeCytes Biotechnologies, headquartered in Barcelona, Spain, has a proven track record of supplying primary human and animal-derived cells to researchers worldwide. Their expertise in cell characterization and in vitro model development ensures consistency and reliability, addressing a critical need in preclinical drug screening and toxicology studies.
“We are excited to collaborate with GVRP to expand our global reach and empower researchers in India with reliable cell-based solutions,” said Jordi Xapellí, the CEO of BeCytes Biotechnologies “With GVRP’s established presence and commitment to research excellence, this partnership will drive impactful scientific advancements.”
Empowering Preclinical Research in India
With AAALAC International accredited and OECD-GLP compliant facilities located in Genome Valley, Hyderabad, GVRP is well-positioned to support the seamless distribution of BeCytes’ offerings. This partnership underscores both organizations’ commitment to enhancing the quality and reproducibility of preclinical research, fostering innovation, and supporting drug development efforts in India and beyond.
For media inquiries and further details, please contact:
E. [email protected] | www.gvrp.in | www.becytes.com
DISCLAIMER
The content and services provided by Kalkine Consultancy India Private Limited (Research Analyst License No: INH000017727, hereinafter referred to as “Kalkine”) are for informational purposes only. The content, including but not limited to articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, charts, animations, and videos (collectively, “Content”), is a service of Kalkine Consultancy India Private Limited and is available for personal and non-commercial use only. Kalkine does not provide personalized financial advice and does not endorse or recommend any individuals, investment products, or services as suitable for specific financial situations. Investors are advised to consult a qualified financial planner or adviser to assess their risk tolerance and portfolio suitability before making any investment decisions. Kalkine accepts no liability for investment losses or any other financial detriment arising from reliance on the Content. Some of the Content on this website may be sourced from third-party providers. Kalkine does not claim ownership over such third-party content and does not guarantee its accuracy, completeness, or reliability. Kalkine shall not be held liable for any errors, omissions, or inaccuracies in third-party content or for any damages or losses resulting from its use. Any images, music, or videos used in the Content are either sourced from publicly available materials, paid subscriptions, or credited to their respective owners where applicable. Kalkine does not claim ownership of third-party media unless explicitly stated. This disclaimer is subject to change without notice. Users are advised to review it periodically for updates.